No Data
No Data
Enanta Pharmaceuticals Stockholders Approve Key Proposals in 2025
Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
Enanta Pharmaceuticals to Present Data for Its Respiratory Syncytial Virus Program at the 13th International RSV Symposium
There's No Escaping Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Muted Revenues Despite A 38% Share Price Rise
Enanta Pharmaceuticals: Hold Rating Amid Delayed Launches and Strategic Advancements
With Enanta Pharmaceuticals Up 46%, Insider Buyers Count Their Returns